检索结果-南通市图书馆

Banking of perinatal mesenchymal stem/stromal cells for stem cellbased personalized medicine over lifetime:Matters arising

在线全文

学校读者我要写书评

暂无评论

World Journal of Stem Cells 2023年第4期15卷 105-119页

作者： Cheng-Hai Li Jing Zhao Hong-Yan Zhang Bin Wang Stem Cell Program of Clinical Research Center People’s Hospital of Zhengzhou University and Henan Provincial People’s HospitalZhengzhou 450003Henan ProvinceChina Department of Clinical Laboratory People’s Hospital of Zhengzhou University and Henan Provincial People’s HospitalZhengzhou 450003Henan ProvinceChina Department of Pharmacy Fuwai Central China Cardiovascular HospitalZhengzhou 450000Henan ProvinceChina Department of Neurosurgery People’s Hospital of Zhengzhou University and Henan Provincial People’s HospitalZhengzhou 450003Henan ProvinceChina

Mesenchymal stromal/stem cells(MSCs)are currently applied in regenerative medicine and tissue *** clinical studies have indicated that MSCs from different tissue sources can provide therapeutic benefits for *** derived from either human adult or perinatal tissues have their own unique advantages in their medical ***,clinical studies are conducted by using of cultured MSCs after thawing or short-term cryopreserved-then-thawed MSCs prior to administration for the treatment of a wide range of diseases and medical ***,cryogenically banking perinatal MSCs for potential personalized medicine for later use in lifetime has raised growing interest in China as well as in many other ***,this has led to questions regarding the availability,stability,consistency,multipotency,and therapeutic efficiency of the potential perinatal MSC-derived therapeutic products after longterm *** opinion review does not minimize any therapeutic benefit of perinatal MSCs in many diseases after short-term *** article mainly describes what is known about banking perinatal MSCs in China and,importantly,it is to recognize the limitation and uncertainty of the perinatal MSCs stored in cryobanks for stem cell medical treatments in whole *** article also provides several recommendations for banking of perinatal MSCs for potentially future personalized medicine,albeit it is impossible to anticipate whether the donor will benefit from banked MSCs during her/his lifetime.

关键词： Mesenchymal stromal/stem cells Adult mesenchymal stromal/stem cells Perinatal mesenchymal stromal/stem cells Perinatal tissue Stem cell bank personalized medicine

personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acta Pharmaceutica Sinica B 2018年第4期8卷 530-538页

作者： Wenxiao Jiang Guiqing Cai Peter C.Hu Yue Wang Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai The University of Texas MD Anderson Cancer Center Department of Molecular and Human Genetics Baylor College of Medicine

Non-small cell lung cancer is a prevalent and rapidly-expanding challenge to modern medicine. While generalized medicine with traditional chemotherapy yielded comparatively poor response rates and treatment results, the cornerstone of personalized medicine using genetic profiling to direct treatment has exalted the successes seen in the field and raised the standard for patient treatment in lung and other cancers. Here, we discuss the current state and advances in the field of personalized medicine for lung cancer, reviewing several of the mutation-targeting strategies that are approved for clinical use and how they are guided by patient genetic information. These classes include inhibitors of tyrosine kinase(TKI), anaplastic lymphoma kinase(ALK), and monoclonal antibodies. Selecting from these treatment plans and determining the optimal dosage requires in-depth genetic guidance with consideration towards not only the underlying target genes but also other factors such as individual metabolic capability and presence of resistance-conferring mutations both directly on the target gene and along its cascade(s).Finally, we provide our viewpoints on the future of personalized medicine in lung cancer, including target-based drug combination, mutation-guided drug design and the necessity for data of population genetics, to provide rough guidance on treating patients who are unable to get genetic testing.

关键词： personalized medicine Non-small cell lung cancer Pharmacogenomics Tyrosine kinase Anaplastic lymphoma kinase Inhibitor Monoclonal antibody

personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer

在线全文

学校读者我要写书评

暂无评论

Acta Pharmaceutica Sinica B 2021年第11期11卷 3406-3416页

作者： Wenxiao Jiang Guiqing Cai Peter Hu Yue Wang Otogenetics Corp. AtlantaGA 30360USA Quest Diagnostics San Juan CapistranoCA 92675USA The University of Texas MD Anderson Cancer Center HoustonTX 77030USA Department of Molecular and Human Genetics Baylor College of MedicineHoustonTX 77030USA

Non-small cell lung cancer is recognized as the deadliest cancer across the *** some areas,it is more common in women than even breast and cervical *** rise,vaulted by smoking habits and increasing air pollution,has garnered much attention and resource in the medical *** first lung cancer treatments were developed more than half a century ***,many of the earlier chemotherapies often did more harm than good,especially when they were used to treat genetically unsuitable *** the introduction of personalized medicine,physicians are increasingly aware of when,how,and in whom,to use certain anti-cancer *** such as tyrosine kinase inhibitors,anaplastic lymphoma kinase inhibitors,and monoclonal antibodies possess limited utility because they target specific oncogenic mutations,but other drugs that target mechanisms universal to all cancers do *** this review,we discuss many of these non-oncogene-targeting anti-cancer agents including DNA replication inhibitors(i.e.,alkylating agents and topoisomerase inhibitors)and cytoskeletal function inhibitors to highlight their application in the setting of personalized medicine as well as their limitations and resistance factors.

关键词： Non-small cell lung cancer personalized medicine Pharmacogenomics Pharmacogenetics Drug resistance Vinca alkaloids Toxoids DNA replication inhibitors

Pharmacomicrobiomics： a novel route towards personalized medicine？

在线全文

学校读者我要写书评

暂无评论

Protein & Cell 2018年第5期9卷 432-445页

作者： Marwah Doestzada Arnau Vich Vila Alexandra Zhernakova Debby P.Y. Koonen Rinse K. Weersma Daan J. TOUW Folkert Kuipers Cisca Wijmenga Jingyuan Fu Departments of Genetics University Medical Center Groningen PO Box 30001 9700 RB Groningen The Netherlands Departments of Paediatrics University Medical Center Groningen PO Box 30001 9700 RB Groningen The Netherlands Departments of Gastroenterology & Hepatology University Medical Center Groningen PO Box 30001 9700 RB Groningen The Netherlands Departments of Clinical Pharmacy & Pharmacology University Medical Center Groningen PO Box 30001 9700 RB Groningen The Netherlands Departments of Laboratory medicine University Medical Center Groningen PO Box 30001 9700 RB Groningen The Netherlands K.G. Jebsen Coeliac Disease Research Centre Department of Immunology University of Oslo P.O. Box 1072 Blindern 0316 Oslo Norway

Inter-individual heterogeneity in drug response is a serious problem that affects the patient＇s wellbeing and poses enormous clinical and financial burdens on a societal level. Pharmacogenomics has been at the forefront of research into the impact of individual genetic background on drug response variability or drug toxicity, and recently the gut microbiome, which has also been called the second genome, has been recog- nized as an important player in this respect. Moreover, the microbiome is a very attractive target for improving drug efficacy and safety due to the opportunities to manipulate its composition. Pharmacomicrobiomics is an emerging field that investigates the interplay of microbiome variation and drugs response and disposi- tion （absorption, distribution, metabolism and excretion）. In this review, we provide a historical overview and examine current state-of-the-art knowledge on the complex interactions between gut microbiome, host and drugs. We argue that combining pharmacogenomics and pharmacomicrobiomics will provide an important foundation for making major advances in personalized medicine.

关键词： gut microbiome drug metabolism personalized medicine

Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of personalized medicine

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Genomics, Proteomics & Bioinformatics 2017年第4期15卷 220-235页

作者： Hala Fawzy Mohamed Kamel Hiba Saeed A.Bagader Al-Amodi Biochemistry Department Faculty of Medicine Umm AL-Qura University Medical Biochemistry Department Faculty of Medicine Ain Shams University

Cancer therapy agents have been used extensively as cytotoxic drugs against tissue or organ of a specific type of cancer. With the better understanding of molecular mcchanislns undcrlying carcinogenesis and cellular events during cancer progression and metastasis, it is now possible to use targeted therapy for these molecular events. Targeted therapy is able to identify cancer patients with dissimilar genetic defects at cellular level for the same cancer type and consequently requires individualized approach for treatment. Cancer therapy begins to shill steadily from the tra- ditional approach of ＂one regimen for all patients＂ to a more individualized approach, through which each patient will be treated specifically according to their specific genetic defects. personalized medicine accordingly requires identification of indicators or markers that guide in the decision mak- ing of such therapy to the chosen patients for more effective therapy. Cancer biomarkcrs are fre- quently used in clinical practice for diagnosis and prognosis, as well as identification ol responsive patients and prediction of treatment response of cancer patient. The rapid breakthrough and development of microarray and sequencing technologies is probably the main tool for paving the way toward ＂individualized biomarker-driven cancer therapy＂ or ＂personalized medicine＂. In this review, we aim to provide an updated knowledge and overview of the currcnt landscape of cancer biomarkers and their role in personalized medicine, emphasizing the impact of gcnomics Oil the implementation of new potential targeted therapies and development of novel cancer biomarkers in improving the outcome of cancer therapy.

关键词： personalized medicine Gene expression Targeted therapy Predictive biomarkers Prognostic biomarkers

Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine

在线全文

学校读者我要写书评

暂无评论

Genes & Diseases 2021年第2期8卷 133-145页

作者： Manish Pratap Singh Sandhya Rai Ashutosh Pandey Nand K.Singh Sameer Srivastava Department of Biotechnology Motilal Nehru National Institute of TechnologyAllahabadUP211004India

Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical *** treatment strategies in colorectal cancer are largely‘one drug fit all’model for patients that display same pathological ***,CRC is a very heterogenous set ofmalignancy that does not support for above *** subtype displays different pathological and genetic *** on these features,therapeutic stratification for individual patients may be designed,which may ultimately lead to improved therapeutic *** this comprehensive review,we have attempted to briefly outline major CRC pathways.A detailed overview of molecular subtypes and their clinical significance has been *** and futuremethods,governing CRC subtyping in the era of personalized therapywith a special emphasis on CMS subtypes of CRC has been ***,discovery and validation of new CRC patient stratification methods,screening for novel therapeutic targets,and enhanced diagnosis of CRC may improve the treatment outcome.

关键词： Biomarkers CMS subtypes Immunotherapy Molecular screening personalized medicine

Healthcare practice strategies for integrating personalized medicine:Management of COVID-19

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2021年第29期9卷 8647-8657页

作者： Wen-Yi Liu Ching-Wen Chien Tao-Hsin Tung Department of Health Policy and Management Bloomberg School of Public HealthJohns Hopkins UniversityMD 21205United StatesShanghai Bluecross Medical Science InstituteShanghai 201100Shanghai ProvinceChina Institute for Hospital Management Tsing Hua UniversityShenzhen CampusShenzhen 518055Guangdong ProvinceChina Evidence-based medicine Center Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical UniversityLinhai 317000Zhejiang ProvinceChina

personalized medicine is the tailor-made clinical treatment to the individual characteristics of each *** may be considered an extension of traditional approaches to knowing and treating *** medicine has the potential to change the way of identification and management of health *** disease 2019(COVID-19)is an infectious disease that primarily affects the patients’*** first case of pneumonia of unknown cause was reported in Wuhan,China on December 31,*** thus,we are quickly approaching the era of personalized *** review discusses the practices currently used in the management of COVID-19 and how they relate to person-alized medicine.

关键词： Healthcare personalized medicine COVID-19 SARS-CoV-2

Stem cell therapy for chronic skin wounds in the era of personalized medicine:From bench to bedside

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Genes & Diseases 2019年第4期6卷 342-358页

作者： Elam Coalson Elliot Bishop Wei Liu Yixiao Feng Mia Spezia Bo Liu Yi Shen Di Wu Scott Du Alexander J.Li Zhenyu Ye Ling Zhao Daigui Cao Alissa Li Ofir Hagag Alison Deng Winny Liu Mingyang Li Rex C.Haydon Lewis Shi Aravind Athiviraham Michael J.Lee Jennifer Moriatis Wolf Guillermo A.Ameer Tong-Chuan He Russell R.Reid The University of Chicago Pritzker School of medicine ChicagoIL 60637USA Molecular Oncology Laboratory Department of Orthopaedic Surgery and Rehabilitation MedicineThe University of Chicago Medical CenterChicagoIL 60637USA Department of Surgery Section of Plastic SurgeryThe University of Chicago Medical CenterChicagoIL 60637USA Key Laboratory of Diagnostic medicine(Ministry of Education) College of Laboratory MedicineChongqing Medical UniversityChongqingChina Department of Orthopaedic Surgery Xiangya Second Hospital of Central South UniversityChangsha 410011China Student Inquiry Research Program Illinois Mathematics and Science Academy(IMSA)AuroraIL60506USA Department of General Surgery The Second Affiliated Hospital of Soochow UniversitySuzhou 215004China Department of Orthopaedic Surgery Chongqing General HospitalChongqing 400013China Department of Biomedical Engineering Northwestern UniversityEvanstonIL 60208USA Department of Surgery Northwestern University Feinberg School of MedicineChicagoIL 60616USA Center for Advanced Regenerative Engineering(CARE) EvanstonIL 60208USA

With the significant financial burden of chronic cutaneous wounds on the healthcare system,not to the personal burden mention on those individuals afflicted,it has become increasingly essential to improve our clinical *** requires the translation of the most recent benchtop approaches to clinical wound repair as our current treatment modalities have proven *** most promising potential treatment options rely on stem cellbased *** cell proliferation and signaling play crucial roles in every phase of the wound healing process and chronic wounds are often associated with impaired stem cell *** approaches involving stem cells could thus be utilized in some cases to improve a body’s inhibited healing *** aim to present the laboratory research behind the mechanisms and effects of this technology as well as current clinical trials which showcase their therapeutic *** the current problems and complications presented by chronic wounds,we hope to show that developing the clinical applications of stem cell therapies is the rational next step in improving wound care.

关键词： Chronic inflammation Chronic wounds Growth factors personalized medicine Skin Stem cells Wound healing

Use of zebrafish embryos as avatar of patients with pancreatic cancer:A new xenotransplantation model towards personalized medicine

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2020年第21期26卷 2792-2809页

作者： Gregorio Di Franco Alice Usai Niccola Funel Matteo Palmeri Ida Elena Rosamaria Montesanti Matteo Bianchini Desirée Gianardi NiccolòFurbetta Simone Guadagni Enrico Vasile Alfredo Falcone Luca Emanuele Pollina Vittoria Raffa Luca Morelli General Surgery Unit Department of Translational Research and New Technologies in Medicine and SurgeryUniversity of PisaPisa 56124Italy Department of Biology University of PisaPisa 56127Italy Division of Surgical Pathology Department of Laboratory of MedicineHospital-University of PisaPisa 56124Italy Division of Medical Oncology Pisa University HospitalPisa 56124Italy Department of Translational Research and New Technologies in medicine and Surgery University of PisaPisa 56124Italy EndoCAS(Center for Computer Assisted Surgery) University of PisaPisa 56124Italy

BACKGROUND The response to chemotherapy treatment of patients with pancreatic ductal adenocarcinoma(PDAC)is difficult to predict and the identification of patients who most likely will benefit from aggressive chemotherapy approaches is *** concept of personalized medicine has emerged in the last years with the objective to tailor the medical treatment to the individual characteristics of each patient,and particularly to the tumor biology of each *** need for invivo xenotransplantation models for cancer patients has increased exponentially,and for this reason zebrafish avatars have gained *** studies were conducted also with PDAC *** To develop a simple,not expensive,diffusible zebrafish embryo model as avatar for patients affected by *** Tumor tissue was taken from the surgical specimen by the *** its fragmentation into small pieces,they are stained with *** pieces of stained tissue were transplanted into the yolk of wt AB zebrafish embryos with a glass capillary *** were incubated at 35°C in E3 medium supplemented with 1%Pen/Strep in the presence or absence of drugs for the following days in respect of the treatment plan(Gemcitabine;Gemcitabine and Oxaliplatin;Gemcitabine and nab-Paclitaxel;5-Fluorouracil and Folinic acid and Oxaliplatin and Irinotecan).The response of zebrafish xenografts to the chemotherapy options has been analyzed by monitoring the fluorescent stained area at 2 h post injection(hpi),1 d and 2 d post injection(dpi).In each time point,the mean size of the stained area was measured by ImageJ and it was normalized with respect to the 1 dpi time point mean relative tumor area(RTA).We evaluated the effect of the chemotherapy exposition comparing the mean RTA of each treated subgroup and the control group and evaluating the percentage reduction of the mean RTA by comparing each treated subgroup with the control *** Between July 2018 and October 2019,a t

关键词： Pancreatic ductal adenocarcinoma Zebrafish embryos personalized medicine Xenotransplantation Chemotherapy efficacy Avatar of oncological patients